Home › Trials › NCT05954910

Evaluating Polatuzumab for Adult Chinese Patients with Diffuse Large B-Cell Lymphoma

The Effectiveness and Safety of Polatuzumab in Real-World Clinical Practice Among Chinese Adult Patients With Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Registry Study

Observational Hoffmann-La Roche · NCT05954910

This study is testing how well Polatuzumab works and how safe it is for adult Chinese patients with Diffuse Large B-Cell Lymphoma who may not have responded to other treatments.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
Ages18 Years and up
SexAll
SponsorHoffmann-La Roche Industry-sponsored
Drugs / interventionscyclophosphamide, doxorubicin, prednisone, polatuzumab
Locations29 sites (Beijing City and 28 other locations)
Trial IDNCT05954910 on ClinicalTrials.gov

What this trial studies

This study aims to assess the effectiveness and safety of Polatuzumab Vedotin in real-world clinical practice among adult Chinese patients diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL). It focuses on measuring progression-free survival (PFS) in different cohorts, including those who are unfit or frail, as well as patients who are relapsed or refractory to previous treatments. The study is observational and does not involve any interventional clinical trials. Participants will be monitored to gather data on their outcomes while receiving Polatuzumab in a clinical setting.

Who should consider this trial

Good fit: Ideal candidates include adult patients diagnosed with DLBCL, particularly those who are unfit or frail, as well as those who have relapsed or are refractory to previous treatments.

Not a fit: Patients currently participating in other interventional clinical trials may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of Polatuzumab for treating DLBCL in a real-world setting, potentially improving patient outcomes.

How similar studies have performed: While this study is observational, similar studies evaluating Polatuzumab in different populations have shown promising results, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Be diagnosed as DLBCL
* Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment
* Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail
* Cohort 3: relapse or refractory to previous treatment

Exclusion Criteria:

* Participant who currently participates in or with plan to participate in any interventional clinical trial
* Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Where this trial is running

Beijing City and 28 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Diffuse Large B-Cell Lymphoma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.